News

Bookmark and Share

This article is in the news archive.

WT Conference in Cambridge: Biomarkers for Brain Disorders: Challenges and Opportunities, 3rd-5th February 2013

The 2nd Wellcome Trust Scientific Conference on ‘Biomarkers for Brain Disorders: Challenges and Opportunities’ will take place in Cambridge on 3rd-5th February 2013. This conference will once again bring together leading neuroscientists from academia and industry involved in genomics, proteomics, diagnostics, imaging and regulatory affairs. Abstract submission will close on December 3rd and registration will close on December 17th.

The discovery and validation of biomarkers in neurological and neurodegenerative diseases is an important challenge for early diagnosis of disease and for the development of therapeutics. Methodological and regulatory aspects of biomarker identification and qualification across a wide spectrum of neurodevelopmental, neurodegenerative and neuropsychiatric diseases will be discussed including, autism, Parkinson's disease, Alzheimers disease, multiple sclerosis and schizophrenia. There will also be a series of break-out sessions for in-depth discussion on the standardization of clinical biomarkers most likely to aid diagnosis and imaging-based studies in biomarker drug discovery. This meeting provides an opportunity for scientists from academia and the commercial sector to discuss the current state of the art in biomarkers and will aid future investment decisions in both sectors.

Scientific organizers

Andreas Jeromin NextGen Sciences Dx, USA
Andy Lockhart GlaxoSmithKline, UK
William Potter formerly Merck, Inc., USA
Giovanni Frisoni
IRCCS Fatebenefratelli, Brescia, Italy

Session Titles:
Neuropsychiatric disorders
Neurological disease
Neurodegenerative diseases
Neurodevelopmental biomarkers and targets
Standardization of clinical biomarkers
Imaging-based studies in biomarker drug discovery

Confirmed Speakers include:
Sabine Bahn, University of Cambridge, UK
Kaj Blennow University of Gothenburg, Sweden
Linda Brady NIMH, USA
Lucie Brujin ALS Association, USA
Chas Bountra Structural Genomics Consortium, UK
Harald Hampel University of Munchen, Germany
Ken Marek Institute for Neurodegenerative Disorders, USA
Jeff Nye Johnson & Johnson, USA
Simon Lovestone King's College London, UK
Kalpana Merchant
 Eli Lilly, USA
Emilio Merlo Pich Roche, Switzerland
Mark Schmidt Johnson & Johnson (Janssen), Belgium
Will Spooren Roche, Switzerland
Charlotte Teunissen  VU University Medical Center Amsterdam, The Netherlands

For more information and for details of registration, please click here.

Posted on 02/11/2012

Further news

Go to the news index page.